Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.90M
Average 0.38M
EVMN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Evommune, Inc.NYSE: EVMN
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin not reported for Q1 FY2026
Context
- Net margin widened in 1 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of -2001.0% for the fiscal year ending Dec 2026, down from -529.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -529.8%+424.6 pp YoY
- LTMMar 2026
- -759.9%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +424.6 pp | -1471.2 pp | -1895.9 pp |
| 3 years | — | -406.4 pp | — |
| 5 years | +213.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -529.8%
- Year-over-year change
- +424.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -529.8% | +424.6pp |
| FY2024 | 2024-12-31 | -954.4% | -273.3pp |
| FY2023 | 2023-12-31 | -681.1% | — |
Net Margin vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 net margin of -759.9% is the 7th highest of the 8 companies compared; the peer median is -41.0%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 67.9% | +108.3 pp | +63.4 pp | |
| LTM Sep 2026 | 16.3% | +63.4 pp | -106.7 pp | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | -3.2% | +34.4 pp | -42.8 pp |
| LTM Mar 2026 | -41.0% | +108.5 pp | -38.2 pp | |
| LTM Mar 2026 | -129.0% | -85.0 pp | -29.0 pp | |
| LTM Mar 2026 | -187.7% | +41.4 pp | -309.2 pp | |
EVMNEvommune, Inc. | LTM Mar 2026 | -759.9% | — | — |
| LTM Mar 2026 | -3566.6% | -3304.7 pp | -492.4 pp | |
CLYMClimb Bio, Inc. | FY2025 | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
| Peer median (excluding EVMN) | -41.0% | +41.4 pp | -42.8 pp | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$7.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.